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In this issue of Structure, Liu and colleagues report the structure of the TNF superfamily member LIGHT
bound to decoy receptor 3 (DcR3). Both LIGHT and DcR3 interact with multiple binding partners. The authors
identify a conserved interaction important for affinity as well as additional interactions that can be targeted to
introduce selectivity.The tumor necrosis factor superfamily
(TNFSF) of cytokines coordinates immune
and inflammatory responses. The central
role of these proteins in immune regula-
tion has led to extensive research efforts
and the development of multiple agents
to sequester the ligands and reduce dis-
ease processes. TNF blockade by recom-
binant TNF receptor 2 (TNFR2)-immuno-
globulin (Ig) fusion protein (etanercept)
or monoclonal antibodies (adalimumab
or infliximab) have been successfully
brought to the clinic and are approved
therapeutics for a range of autoimmune
conditions; similarly, an antibody target-
ing RANKL (denosumab) has been ap-
proved for treatment of osteoporosis,
while a BAFF-blocking antibody (belimu-
mab) has beenmarketed for the treatment
of systemic lupus erythematosus (Croft
et al., 2013). Conversely, activation of
the immune system by activating selected
members of the TNFRSF may be of
benefit in oncology indications (Moran
et al., 2013). Most members of the TNFSF
have a single cognate receptor, but others
bind multiple receptors, and there is
myriad complexity in the web of interac-
tions that result. Despite the extensive
study of this pathway, the precise mecha-
nistic detail of the functional promiscuity
remains elusive.
LIGHT (TNFSF14) is known to activate
two members of the TNFRSF: the herpes
virus entry mediator (HVEM; TNFRSF14)
and lymphotoxin beta receptor (LTbR;
TNFRSF3). LIGHT-mediated HVEM acti-
vation signals as a costimulatory axis for
T cell proliferation and cytokine produc-
tion. In contrast, LTbR is expressed on
nonhematopoietic cells and follicular den-
dritic cells and has a role in lymphoid
organogenesis and propagation of inflam-matory signals (Bjordahl et al., 2013).
LTbR is also activated by the heterotrimer
LTab2, while HVEM activates the Ig family
member BTLA. To add further complexity,
in humans, LIGHT signaling is naturally
modulated by interactions with the solu-
ble decoy receptor DcR3 (TNFRSF6B).
Intriguingly, DcR3 sequesters three
TNFSF ligands (LIGHT, TL1A [TNFSF15],
and FasL [TNFSF6]), which share rela-
tively low sequence identity (30%)
(Steinberg et al., 2011) (Figure 1A). DcR3
is absent in mice, complicating interpreta-
tion of murine models of inflammatory
diseases.
In this issue of Structure, Liu et al.
(2014) describe the LIGHT-DcR3 com-
plex. As with previously reported TNFSF
and TNFSF-TNFRSF structures, LIGHT
protomers possess the canonical TNFSF
jelly-roll topology arranged in a ‘‘pear-
shaped’’ homotrimeric assembly, while
the LIGHT-DcR3 complex structure forms
a 3:3 receptor:ligand assembly. The DcR3
receptormolecules bind the LIGHT homo-
trimer at the protomer-protomer inter-
faces to form a 3-fold symmetric complex.
This symmetric interaction with DcR3 is in
contrast with biophysical studies that
demonstrated that the stoichiometry of
LTbR interactions with LIGHT (or LTab2)
and that only two copies of LTbR (rather
than three) bind a single molecule of the
homo- or hetero-trimeric ligand (Eldredge
et al., 2006). Further work, guided by this
structure, will be necessary to understand
the apparent loss of symmetry in LIGHT-
LTbR interactions and the biological impli-
cations for pathway activation.
A comparison of the structure of
LIGHT-DcR3 with the TL1A-DcR3 com-
plex previously determined by the same
group (Zhan et al., 2011) reveals thatStructure 22, September 2, 2014DcR3 recognizes each ligand (LIGHT,
TL1A) in a broadly similar manner
(Figure 1B). Despite the low sequence
identity, an invariant tyrosine residue
and surrounding main chain atoms from
the LIGHT (or TL1A) DE-loop form a
conserved binding patch recognized by
DcR3. The analogous residue has been
shown to be critical for bioactivity in
TNFSF members LT and Apo2L/TRAIL
(TNFSF10) (Goh et al., 1991; Hymowitz
et al., 2000) and makes conserved
interactions in other TNFSF-TNFRSF
complexes, such as LTa-TNFR1 (Protein
Data Bank [PDB] code 1TNR), Apo2L/
TRAIL-DR5 (PDB code 1D0G), and TNF-
TNFR2 (PDB code 3ALQ). The tyrosine
at this position is conserved in FasL and
makes similar interactions with DcR3 in
a deposited structure of FasL bound to
DcR3 from Almo and colleagues (PDB
code 4MSV). These underlying structural
similarities suggest this interaction ac-
counts for the broad specificity of DcR3,
while modulatory interactions elsewhere
in the ligand interface limit selectivity
to TL1A, FasL, and LIGHT (Figures 1A
and 1B).
The availability of these complementary
structures greatly facilitates targeted
engineering of the ligand-receptor inter-
faces to introduce selectivity into other-
wise promiscuous binding partners. In
particular, comparison of these struc-
tures can facilitate design hypotheses to
deconvolute the overlapping signaling
pathways of HVEM and LTbR as well as
the role of DcR3. As proof of concept,
Liu et al. (2014) generated chimeras of
LIGHT containing transplanted loops
from TL1A. A chimera containing the
GH-loop of TL1A in the context of
LIGHT resulted in a protein that retainsª2014 Elsevier Ltd All rights reserved 1221
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Figure 1. Structural Basis of Overlapping Signaling Pathways
Involving LIGHT and DcR3
(A) DcR3 interaction network. TNF ligands TL1A and FasL interact with TNFRs
DR3andFas, respectively. LIGHT interactswith twoknowncognate receptors:
LTbR and HVEM. LTbR also binds LTab2. A conserved tyrosine (gray sticks)
forms part of a binding patch on Fas, TL1A, and LIGHT, which is recognized
by the decoy receptor DcR3. Other members of the TNFSF such as LT,
Apo2L/TRAIL, and LTab2 also possess a tyrosine at this position but lack the
ability to interact with DcR3, indicating that selectivity determinants elsewhere
are critical for ligand-receptor interactions. Adapted from Liu et al. (2014).
(B) Schematic view of LIGHT-DcR3 complex. Trimeric TNF ligand LIGHT
(shown as blue ovals) is embraced by three DcR3 receptors (salmon) to
form a heterohexameric complex. Cartoon representation of one LIGHT pro-
tomer is shown with b strands labeled. LIGHT residue Y173 (cyan spheres)
forms part of a conserved binding patch in the DE loop (arrow), which is
recognized by CRD2 of DcR3. Receptor-specific selectivity regions include
the GH and EF loops; chimeric LIGHT mutants 1 (orange star) and 2 (green
star) contain transplants of these respective loops from TL1A.
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DcR3, but with an 130-fold
reduction in affinity for the
cognate LIGHT receptor
HVEM. A second chimera in
which the EF-loop of TL1A
was incorporated into LIGHT
exhibits an 10-fold loss of
affinity for DcR3 and an 15-
fold loss of affinity for HVEM.
Notably, both mutant proteins
bound the other LIGHT recep-
tor, LTbR,with similar affinities
to thewild-type protein. These
chimeras permit a limited
deconvolution of the LIGHT-
HVEM and LIGHT-LTbR path-
ways. In an in vitro assay,
Liu et al. (2014) demonstrated
that both chimeric proteins
have an impaired ability to
activate apoptosis as com-
pared to wild-type LIGHT,
suggesting that the reduction
in apoptotic activity is likely a
result of an impaired LIGHT-
HVEM pathway.
More extensive structure-
inspired efforts using chi-
meras, monoclonal anti-
bodies, or combinatorial
biology approaches, such as
phage display targeting either
the ligands (TL1A, LIGHT,
FasL) or receptors (HVEM,
LTbR, Fas, DcR3), may lead
to the generation of selec-
tive proteins that can be
used to delineate the bio-
logical roles of specific
ligand-receptor interactions
within this family. This could
generate tools that could be
used to determine the role
of specific DcR3 interactions
in human biology or clarify
interpretations of murine
models of human disease
by selectively introducing
DcR3 mutants into trans-genic mouse. Similar approaches with
structure-driven targeted mutations to
Apo2L/TRAIL have introduced selectivity1222 Structure 22, September 2, 2014 ª2014for the related TNFRSF members DR4
and DR5 and have been used to show
that DR5 may drive apoptosis moreElsevier Ltd All rights reservedstrongly than DR4 (Kelley
et al., 2005). Further bio-
chemical characterization of
engineered ligands and re-
ceptors holds promise for
teasing apart the complex
signaling networks in the
TNFSF to better elucidate
their role in human diseases.
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